Cargando…
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
IMPORTANCE: Thyroid eye disease can be a debilitating autoimmune disorder characterized by progressive proptosis or diplopia. Teprotumumab has been compared with placebo in randomized clinical trials, but not with intravenous methylprednisolone (IVMP), which sometimes is used in clinical practice fo...
Autores principales: | Douglas, Raymond S., Dailey, Roger, Subramanian, Prem S., Barbesino, Giuseppe, Ugradar, Shoaib, Batten, Ryan, Qadeer, Rana A., Cameron, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855315/ https://www.ncbi.nlm.nih.gov/pubmed/35175308 http://dx.doi.org/10.1001/jamaophthalmol.2021.6284 |
Ejemplares similares
-
Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone
por: Douglas, Raymond S, et al.
Publicado: (2021) -
LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022) -
Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022) -
Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022) -
Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021)